Imagion Biosystems has achieved a key milestone in its progress to first-in-human testing with the successful completion of a toxicology safety study of its lead MagSense® nanoparticle formulation for the detection of HER2 metastatic breast cancer.
Read the announcement.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)